Clinical outcomes of patients according to opioid use at baseline over 12-month longitudinal follow-up.
| . | Using Opioids at Baseline (n = 116) . | Not Using Opioids at Baseline (n = 913) . | P . | Unadjusted HR (95% CI) . | P value . | Adjusted HR (95% CI) . | P . |
|---|---|---|---|---|---|---|---|
| Flare of disease activity (%) | 15 (12.9) | 139 (15.2) | .51 | 0.87 (0.51–1.49) | .61 | 0.67 (0.34–1.35) | .26 |
| Glucocorticosteroid prescription due to uncontrolled IBD activity (%) | 5 (4.3) | 66 (7.2) | .24 | 0.60 (0.24–1.49) | .27 | 0.48 (0.16–1.44) | .19 |
| Escalation of IBD therapy due to uncontrolled IBD activity (%) | 13 (11.2) | 117 (12.8) | .62 | 0.90 (0.51–1.59) | .71 | 0.85 (0.42–1.71) | .64 |
| Hospitalization due to uncontrolled IBD activity (%) | 9 (7.8) | 31 (3.4) | .022 | 2.40 (1.14–5.03) | .021 | 2.15 (0.81 -5.74) | .13 |
| Intestinal resection due to uncontrolled IBD activity (%) | 6 (5.2) | 11 (1.2) | .002 | 4.44 (1.64–12.0) | .003 | 7.09 (1.63–30.9) | .009 |
| Any of the above (%) | 24 (20.7) | 165 (18.1) | .49 | 1.19 (0.78–1.83) | .42 | 0.97 (0.56–1.69) | .91 |
| . | Using Opioids at Baseline (n = 116) . | Not Using Opioids at Baseline (n = 913) . | P . | Unadjusted HR (95% CI) . | P value . | Adjusted HR (95% CI) . | P . |
|---|---|---|---|---|---|---|---|
| Flare of disease activity (%) | 15 (12.9) | 139 (15.2) | .51 | 0.87 (0.51–1.49) | .61 | 0.67 (0.34–1.35) | .26 |
| Glucocorticosteroid prescription due to uncontrolled IBD activity (%) | 5 (4.3) | 66 (7.2) | .24 | 0.60 (0.24–1.49) | .27 | 0.48 (0.16–1.44) | .19 |
| Escalation of IBD therapy due to uncontrolled IBD activity (%) | 13 (11.2) | 117 (12.8) | .62 | 0.90 (0.51–1.59) | .71 | 0.85 (0.42–1.71) | .64 |
| Hospitalization due to uncontrolled IBD activity (%) | 9 (7.8) | 31 (3.4) | .022 | 2.40 (1.14–5.03) | .021 | 2.15 (0.81 -5.74) | .13 |
| Intestinal resection due to uncontrolled IBD activity (%) | 6 (5.2) | 11 (1.2) | .002 | 4.44 (1.64–12.0) | .003 | 7.09 (1.63–30.9) | .009 |
| Any of the above (%) | 24 (20.7) | 165 (18.1) | .49 | 1.19 (0.78–1.83) | .42 | 0.97 (0.56–1.69) | .91 |
aχ2 for comparison of data between groups.
Clinical outcomes of patients according to opioid use at baseline over 12-month longitudinal follow-up.
| . | Using Opioids at Baseline (n = 116) . | Not Using Opioids at Baseline (n = 913) . | P . | Unadjusted HR (95% CI) . | P value . | Adjusted HR (95% CI) . | P . |
|---|---|---|---|---|---|---|---|
| Flare of disease activity (%) | 15 (12.9) | 139 (15.2) | .51 | 0.87 (0.51–1.49) | .61 | 0.67 (0.34–1.35) | .26 |
| Glucocorticosteroid prescription due to uncontrolled IBD activity (%) | 5 (4.3) | 66 (7.2) | .24 | 0.60 (0.24–1.49) | .27 | 0.48 (0.16–1.44) | .19 |
| Escalation of IBD therapy due to uncontrolled IBD activity (%) | 13 (11.2) | 117 (12.8) | .62 | 0.90 (0.51–1.59) | .71 | 0.85 (0.42–1.71) | .64 |
| Hospitalization due to uncontrolled IBD activity (%) | 9 (7.8) | 31 (3.4) | .022 | 2.40 (1.14–5.03) | .021 | 2.15 (0.81 -5.74) | .13 |
| Intestinal resection due to uncontrolled IBD activity (%) | 6 (5.2) | 11 (1.2) | .002 | 4.44 (1.64–12.0) | .003 | 7.09 (1.63–30.9) | .009 |
| Any of the above (%) | 24 (20.7) | 165 (18.1) | .49 | 1.19 (0.78–1.83) | .42 | 0.97 (0.56–1.69) | .91 |
| . | Using Opioids at Baseline (n = 116) . | Not Using Opioids at Baseline (n = 913) . | P . | Unadjusted HR (95% CI) . | P value . | Adjusted HR (95% CI) . | P . |
|---|---|---|---|---|---|---|---|
| Flare of disease activity (%) | 15 (12.9) | 139 (15.2) | .51 | 0.87 (0.51–1.49) | .61 | 0.67 (0.34–1.35) | .26 |
| Glucocorticosteroid prescription due to uncontrolled IBD activity (%) | 5 (4.3) | 66 (7.2) | .24 | 0.60 (0.24–1.49) | .27 | 0.48 (0.16–1.44) | .19 |
| Escalation of IBD therapy due to uncontrolled IBD activity (%) | 13 (11.2) | 117 (12.8) | .62 | 0.90 (0.51–1.59) | .71 | 0.85 (0.42–1.71) | .64 |
| Hospitalization due to uncontrolled IBD activity (%) | 9 (7.8) | 31 (3.4) | .022 | 2.40 (1.14–5.03) | .021 | 2.15 (0.81 -5.74) | .13 |
| Intestinal resection due to uncontrolled IBD activity (%) | 6 (5.2) | 11 (1.2) | .002 | 4.44 (1.64–12.0) | .003 | 7.09 (1.63–30.9) | .009 |
| Any of the above (%) | 24 (20.7) | 165 (18.1) | .49 | 1.19 (0.78–1.83) | .42 | 0.97 (0.56–1.69) | .91 |
aχ2 for comparison of data between groups.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
